Prospective observation of Clostridium histolyticum collagenase for the treatment of Dupuytren's disease in 788 patients: the Austrian register.

Introduction: Since March 2011, the microbial collagenase of Clostridium histolyticum (Xiapex®, Swedish Orphan Biovitrum AB, Stockholm, Sweden) has become available in the European Union for treatment of Dupuytren's disease. The purpose of this study was to evaluate potential safety risks of Xiapex® and to contribute to a better understanding for its use.

Methods: A prospective, non-interventional, observational study using Xiapex® for Dupuytren's disease named XIANIS was conducted between 1.

[Non-invasive correction of congenital ear deformities with the EarWell Correction System: a prospective study].

Background: Congenital ear deformities occur in 5 % of all newborns. Molding of the ear is possible during the first six weeks of life because of the maternal hormones which are still circulating in the newborns. For several years we have been using the EarWell™ Correction System, which allows us to correct ear deformities within the first weeks of life.